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Experimental allergic encephalomyelitis  (EAE) 1 is an autoimmune syndrome ini- 
tiated  by  the  injection  of myelin  basic  protein  (BP)  in  an  appropriate  adjuvant. 
Inbred  Lewis  (Le)  rats develop acute  hindquarter  paralysis  10-14  d  subsequent  to 
challenge with guinea pig-derived BP in complete Freund's adjuvant  (CFA).  Spon- 
taneous recovery from paralysis occurs within a few days. Le rats that have recovered 
from paralysis are resistant  to a  secondary challenge with BP-CFA.  The manner in 
which  this  acquired  resistance  mechanism  operates  is  unknown.  In  addition  to 
acquired resistance manifested by EAE-recovered Le rats, other inbred strains of rats 
display  genetic  resistance.  Disease susceptibility  is  reported  to  be controlled  by an 
immune  response  (Ir)  gene closely linked  to  the  major histocompatibility complex 
(MHC)  (1-4). The cellular mechanisms that mediate genetic resistance to disease are 
poorly understood partly as a result of difficulties encountered in the adoptive transfer 
of allogeneic cells. 
The study reported here was prompted by an observation of resistance to clinical 
EAE induction  in a  large number of Lewis (designated Le-R) rats.  Breeding experi- 
ments  suggested  that  resistance  was  a  dominant,  autosomal  genetic  trait.  Le-R 
leukocytes are apparently unable to transfer disease adoptively to naive Le recipients, 
however,  Le leukocytes readily transfer disease into  naive Le-R recipients,  Because 
cellular exchange in other susceptible/resistant rat strain combinations is hindered by 
histocompatibility  barriers,  the  Le/Le-R  system  presents  a  unique  opportunity  to 
investigate  cellular  and/or  humoral  aspects  of genetic  resistance  to  autoimmune 
neural tissue destruction. 
* Supported in part by grant RG-1203-A-I from the National Multiple Sclerosis Society, and by U. S. 
Public Health Service grant AI-07025. 
i Abbreviations used in this paper: BN, Brown Norway; BP, myelin basic protein; C, complement; CFA, 
complete Freund's adjuvant; Con A, concanavalin A; EAE, experimental allergic encephalomyelitis; EF, 
encephalitogenic fragment of myelin basic protein; Ir gene, immune response  gene; Le, Lewis; Le-R, Lewis- 
resistant; MHC, major histocompatibility  complex; OA, ovalbumin. 
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Materials  and  Methods 
Rats.  The colony of Le-R rats was originally obtained from Simonsen Laboratories (Gilroy, 
Calif.) and was initially susceptible to EAE induction (5). The colony had been maintained as 
a closed colony for approximately 5 yr before the initiation of this study. Within this colony, 
rats  were  randomly bred.  Conventional Le  rats  (RTI-1)  were  obtained  from  (a)  Simonsen 
Laboratories, (b) Microbiological Associates, (Walkersville, Md.), and (c) The Rocky Mountain 
Laboratories,  (Hamilton, Mont.).  Le  rats  from  each  of these  sources  displayed comparable 
susceptibility to EAE induction. Buffalo rats  (RTlob) were obtained from Simonsen Labora- 
tories and Brown Norway (BN)  rats (RTI-n) were obtained from Microbiological Associates. 
Rats were provided access to food and water without restriction, and were hand-watered during 
periods of paralysis. 
Preparation of BP and Encephalitogenic Peptide.  BP  was  prepared  from  Hartley  guinea pig 
brains and spinal cords by the procedure of Deibler et al. (6),  and characterized as previously 
described (7). The encephalitogenic fragment (EF) of BP, comprising amino acid residues 68- 
88, was a  generous gift by Doctors R. B. Fritz and R.  F. Kibler, Emory University School of 
Medicine, Atlanta, Ga. The methods for isolating and characterizing EF have been described 
in detail elsewhere (8). 
Induction of EAE.  Paralytic EAE was induced by a single injection of 50 #g of BP in CFA as 
previously described (7).  In each experiment in which the EAE susceptibility of Le-R rats was 
assessed, Le rats were also included as positive controls to insure that emulsions had the capacity 
to induce paralysis in susceptible recipients. 
Clinical Evaluation.  Rats were assigned a daily clinical grade by the following criteria: 0, no 
sign of neurologic impairment; 1, flaccid tail; 2, hindquarter weakness; 3, hindquarter paralysis. 
Histologic Evaluation.  Brains and spinal cords obtained at  day  17  post-BP-CFA challenge 
were fixed in formalin and then stained with hematoxylin and eosin. The degree of severity of 
neural tissue lesions was evaluated by the criteria of Gasser et al. (3). 
Serotype Analysis.  An anti-Le antiserum was raised in BN rats by five weekly intraperitoneal 
injections of 3  ×  107 Le spleen cells. This antiserum was diluted in complement (C)  fixation 
diluent (9)  in a  i:5 ratio, which was  found to be the optimum concentration for killing Le 
target cells in preliminary experiments. Target spleen cells, obtained from  Le, Le-R, Buffalo, 
and BN rats, were incubated with the anti-Le serum for 30 min at 37°C (5 ×  10  ~ leukocytes/ 
ml).  An equal  volume of freshly  prepared  homologous rat  serum was  added  as a  source of 
complement and the mixture incubated for an additional 30 min. Cytotoxicity was determined 
by  trypan  blue or  nigrosin dye  exclusion.  The  percent  specific  cytotoxicity  was  calculated 
according to the following formula: 
No. viable cells after treatment with 1 
BN anti-Le serum plus C / 
percent specific cytotoxicity =  1 -  No. viable cells after treatment wit~]  ×  100. 
normal BN serum plus C_I 
Migration Inhibition Assay.  Cellular reactivity specific  for  BP or  EF was  determined by a 
direct migration inhibition assay described in detail previously (7,  10)+ 
Passive Transfer of EAE.  Spleen cells were obtained at days  12-14 post-BP-CFA challenge. 
The cells were cultured for 3 d in the presence of 1 ~g/ml of concanavalin A  (Con A) or 1 p,g/ 
ml of BP according to the procedure described previously (11,  12). At the end of the culture 
period,  cell  viability was  determined  by dye  exclusion, and  cells were  infused into normal 
recipients by intraperitoneal injection. Data describing the specificity of the passive transfer of 
EAE is to be presented in detail elsewhere.  2 
Results 
Susceptibility  to EAE Induction  by Le and Randomly  Bred Le-R Rats.  Le  rats  obtained 
from three  independent sources were susceptible to EAE induction (Fig.  1).  Out of a 
tlinrichs,  D.  J.,  C.  Roberts,  and  F.  J.  Waxman.  Regulation of paralytic  experimental  allergic 
encephalomyelitis  in rats:  susceptibility  to active and passive disease reinduction. Manuscript submitted 
for publication. WAXMAN, PERRYMAN, HINRICHS, AND COE  63 
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Fxo.  1.  Susceptibility to EAE induction of Le rats. Rats were injected with 50 p.g of BP in CFA at 
various ages, and subsequent clinical signs were monitored. The data are expressed as the maximum 
clinical response  as assessed by the following  criteria: 0, no symptoms; 1, flaccid tail; 2, hindquarter 
weakness; 3, hindquarter paralysis. Each datum point (O) indicates the response of an individual 
rat, 
total of 161 Le rats tested, 92% developed paralysis (grade 3). EAE susceptibility was 
not  age dependent  within  the  period  tested  (43-  to  263-d-old  at  time of BP-CFA 
challenge). 
In contrast, only 23% of Le-R rats developed paralysis out of 180 randomly bred 
Le-R rats tested (Fig. 2). Resistance was most evident when Le-R rats were <100 d of 
age at the time of BP-CFA challenge. However, resistance was also apparent in older 
Le-R rats, since a majority of these animals displayed mitigated neurologic symptoms. 
In those Le-R rats that did develop clinical manifestations of EAE, the day of onset 
of symptoms was delayed, disease severity was reduced, and the duration of clinical 
signs was abbreviated, compared with Le rats (Fig. 3). This mitigated disease pattern 
was again most evident in young Le-R rats. 
In  addition  to  clinical  evaluations,  brains  and  spinal  cords  of selected  EAE- 
susceptible and  EAE-resistant  Le-R rats were evaluated  by histologic examination 
(Table I). Neural tissue lesions characteristic for EAE were seen in BP-CFA-challenged 
Le rats.  Similar lesions were seen  in  Le-R rats, which  had developed clinical  EAE 
subsequent  to BP-CFA challenge. In Le-R rats, that were resistant  to clinical  EAE, 
lesions were minimal or absent. Thus, evaluation of EAE by histopathologic criteria 
corresponded with clinical assessments. 
Inheritance of EAE Resistance by Progeny of Le-R Rats Selected for EAE Susceptibility  or 
Resistance.  Because there was some heterogeneity in the susceptibility of individual 
Le-R rats, it was possible that the Le-R colony might contain two separate popula- 
tions:  one being susceptible, the other resistant.  In order to determine if susceptible 
and resistant  Le-R rat  populations could be selected by breeding,  young randomly 64  RESISTANCE  TO  EXPERIMENTAL  ALLERGIC  ENCEPHALOMYELITIS 
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F=G.  2.  Age-related  resistance to EAE induction of random]y bred Le-R rats. Rats were injected 
with 50/~g of" BP in CFA at various ages, and subsequent c[inlcal signs were monitored. The data 
are expressed as the maximum clinical response as assessed  by the following criteria: 0, no symptoms; 
1, flaccid tail; 2, hindquarter weakness; 3, hindquarter paralysis. Each datum point (0) indicates 
the response of an individual rat. 
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Fxt~.  3.  Reduced severity of disease in  EAE-susceptible Le-R  rats.  Le  (age 43-263  d)  rats  (0), 
young (age 43-65  d)  Le-R rats  (I), and older (age 98-310  d)  Le-R rats (&)  were evaluated  for 
clinical neurologic impairment on days  10-17 after BP-CFA challenge. The data are expressed as 
the mean clinical grade :1:1  SEM for 160 Le rats, 9 young Le-R rats, and 81 older Le-R rats (rats 
that displayed no signs of neurologic impairment are not included in these data). Clinical grades 
were assigned according to the following criteria: 0, no symptoms;  1, flaccid tail;  2,  hindquarter 
weakness; 3, hindquarter paralysis. The mean +  I SEM day of onset of clinical signs of EAE were: 
Le rats,  10.8 +  0.1  d; young Le-R rats,  13.1 +  0.6d; older Le-R rats,  12.1 ±  0.1 d. The mean :t:  1 
SEM duration of clinical signs were: Le rats, 5.4 +  0.l  d; young Le-R rats, 2.9 _  0.4 d; older Le-R 
rats, 4.7 +  0.2 d. 
bred  Le-R  rats were challenged  with BP-CFA  and  classified as susceptible or resistant. 
Breeding  trios  composed  of rats  selected  for  resistance,  and  trios  of rats  selected  for 
susceptibility  were established.  The  F1  progeny  from  resistant  parents,  or susceptible 
parents,  were likewise classified according  to their susceptibility. F2 progeny  were then 
produced  by  brother-sister  mating  of  susceptible  Fa  rats,  or  resistant  F1  rats.  F3 WAXMAN,  PERRYMAN,  HINRICHS, AND COE 
TABLE  I 
Histologic Evaluation of Neural Tissue Lesions in EAE-susceptible or EAE- 
resistant Le-R Rats 
Maxi- 
mum  Lesion 
Strain  Group  Rat no.  clinical  severity~: 
grade* 
Le  EAE-susceptible§  1  3  +++ 
2  3  ++++ 
Le-R  Normal[[  3  0  0 
4  0  0 
Le-R  EAE-susceptible§  5  2  ++ 
6  2  ++++ 
7  2  + 
8  2  ++ 
9  2  +++ 
Le-R  EAE-resistant§  10  0  0 
11  0  0 
12  0  ++ 
13  0  :l: 
14  0  0 
* Clinical grades were assigned  by the following criteria: 0, no symptoms;  1, 
flaccid tail; 2, hindquarter weakness; 3, hindquarter paralysis. 
:~ Spinal cords were fixed in formalin and then stained with hematoxylin and 
eosin. The degree of severity of neural tissue lesions was graded as described 
by  Gasser  et  al.  (3). 0,  no  perivascular,  meningeal, or  intraparenchymal 
infiltrates of mononuclear cells; :l:,  only one cellular infiltrate in a spinal  root 
or in leptomeninges; +, several infiltrates in spinal  roots and occasionally  in 
spinal cord; ++, many infiltrates in the roots and at least one infiltrate in 
the cord at X 30 field; +++, confluent infiltrates  in the roots, many infiltrates 
in the cord, occasional  infiltrates in the cerebrum; ++++, confluent infil- 
trates in roots an d spinal cord, several infiltrates  in cerebrum. 
§ Neural tissue specimens were obtained from the rats at day 17 post-BP-CFA 
injection. 
[1 Neural tissue specimens were obtained from rats that had not been challenged 
with BP-CFA. 
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progeny  of  entirely  resistant  lineage  were  produced  by  brother-sister  mating  of 
resistant  F2 rats. 
The  EAE  susceptibility  of these  Le-R rats  is shown  in  Table  II.  A  majority of FI 
and F2 Le-R rats of either susceptible or resistant lineage was resistant when challenged 
with BP-CFA at  7-11  wk of age. Thus, the susceptibility of F1 and F2 progeny had no 
relationship to their ancestry.  F~ rats were uniformly resistant  to EAE induction at all 
ages  tested.  These  data  suggest  that  a  single  inbred  population  with  phenotypic 
resistance  to EAE induction  had  been selected from the Le-R colony. 
EAE Susceptibility of (Le  ×  Le-R)Ft and Backcross Progeny.  In order to determine if 
the EAE resistance displayed by Le-R rats was a  genetic trait,  100% EAE-resistant  Fa 
Le-R  rats  were  crossed  with  Le  rats,  and  the  EAE  susceptibility  of (Le  ×  Le-R)F1 
progeny was assessed  (Table III). The Ft progeny of Le males ×  Le-R females, as well 
as  the offspring of Le females  ×  Le-R males were resistant  to  EAE  induction.  Both 
male and  female FI  progeny  were  resistant.  Thus,  EAE  resistance  in  7-  to 8-wk-old 
(Le ×  Le-R)F1 rats appeared  to be inherited  as a  dominant,  autosomal  trait. 
(Le ×  Le-R)F1 rats were then  backcrossed  to Le rats,  and  the progeny were tested 66  RESISTANCE TO  EXPERIMENTAL ALLERGIC  ENCEPHALOMYELITIS 
TAm,  W II 
Susceptibility to EAE by Progeny of Le-R Rats Selected  for EAE Resistance or EAE Susceptibility 
Percent sensitive 
Age when  (maximum clin- 
Strain  Lineage*  Genera-  challenged  Percent  ical grade at-  No. of 
tion  with BP-  resistant  tained)$  rats tested 
CFA 
1  2  3 
wk 
Le  --  --  7-11  1  2  6  91  95§ 
Le-R  Resistant  FI  7-11  68  4  23  5  72 
Le-R  Resistant  F2  7-11  51  9  28  12  67 
Le-R  Susceptible  Fl  7-11  60  8  30  2  40 
Le-R  Susceptible  F2  7-11  69  15  8  8  26 
Le-R  Resistant  F~  7-11  100  0  0  0  49 
Le-R  Resistant  F3  26-42  100  0  0  0  26 
* Breeders  were classified  as  EAE sensitive  if they displayed a  clinical  grade of 2 or 3 after BP-CFA 
challenge, or classified as EAE resistant  if they showed no signs of neurological  impairment after BP-CFA 
challenge. 
$Clinical  grades were assigned by  the  following  criteria:  1,  flaccid  tail;  2,  hindquarter weakness;  3, 
hindquarter paralysis. 
§ Only those Le rats that were challenged at 7-11 wk of age are included in this table. 
TABLE III 
EAE Susceptibility of (Le ×  Le-R)F1 and Backcross Rats* 
Percent 
sensitive 
Percent  (maximum  No. of rats 
Group  resistant  clinical grade  tested 
attained)$ 
1  2  3 
Le§  0  0  0  100  19 
(I~ X ~-R)F,II,  ¶  95  3  0  2  6O 
(Le ×  Le-R)Fj ×  Le  25  4  25  46  71"* 
* Rats were injected with BP-CFA at 7-8 wk of age. 
:]: Clinical grades were assigned  by the following criteria:  1,  flaccid  tail;  2, 
hindquarter weakness; 3, hindquarter paralysis. 
§ These Le rats were included in each experiment as positive controls for the 
encephalitogenicity of BP-CFA emulsions. 
N  Of the (Le ×  Le-R)FI rats tested, 36 were derived from matings between 
Le-R males and Le females whereas the remaining 24 were derived from 
matings between Le males and Le-R females. 34 of the (Le ×  Le-R)F1 rats 
were females, and 26 were males. 
¶ The Le-R rats used as breeders for the production of (Le ×  Le-R)FI  and 
backcross rats were 100% EAE-resistant  F3 rats (Table II). 
** The  X  2 value  (4.68)  obtained when comparing resistant  vs.  susceptible 
backcross rats was significantly different (P< 0.05) from the expected value 
for three genes. 
for their susceptibility to EAE induction (Table III). A  total of 46% of the backcross 
progeny developed paralysis, whereas 29%  developed EAE  with  mitigated severity. 
25% of the backcross progeny was completely resistant to EAE induction. These data 
suggest that EAE resistance is mediated by one or two genes. 
RTI Serotype of Le-R Rats.  It is possible that Le-R rats manifest EAE resistance as 
a  result of the accidental interbreeding of Le and non-Le white rats.  In order to test WAXMAN, PERRYMAN, HINRICHS, AND COE  67 
this possibility, an anti-Le alloantiserum  was raised  in  BN rats.  Target spleen cells 
from F1 and F2 Le-R rats of either susceptible or resistant  lineage were treated with 
anti-Le  plus  C',  and  specific  cytotoxicity  was  assessed  by  dye  exclusion.  In  each 
experiment, spleen cells from Le rats were included as positive controls. Spleen cells 
from Buffalo or BN rats served as negative controls. 
The anti-Le serum plus C' treatment was cytotoxic for Le cells (79% mean specific 
percent cytotoxicity) but  not  for Buffalo (3%  mean specific percent cytotoxicity) or 
BN  (9%  mean specific cytotoxicity) cells.  This antiserum  was cytotoxic  (68% mean 
specific percent cytotoxicity) for Le-R spleen cells independent of their lineage. Thus, 
Le-R rats shared at least some portion of the Le MHC antigen complex. This protocol 
would  not  distinguish  between  homozygous  vs.  heterozygous  RTI-1 +  Le-R  rats, 
however, the results of breeding experiments presented above would seem to exclude 
the possibility that Le-R rats were heterozygous. 
Cellular Reactivity of Le-R Rats.  It is possible that Le-R rats manifest EAE resistance 
because of a  general  impairment in their ability to develop cellular reactivity when 
challenged  with antigen.  In order to test this possibility, Le-R rats were challenged 
with BP-CFA and classified as susceptible or resistant. At day 21  postchallenge, rats 
received an injection of ovalbumin (OA)  in CFA. Cellular reactivity specific for OA, 
as assessed by macrophage migration inhibition,  was determined at day 21  after the 
second injection. 
Both EAE susceptible and resistant Le-R rats developed cellular reactivity specific 
for  OA  after  challenge  with  OA-CFA  (Fig.  4A).  These  data  suggest  that  EAE 
resistance is not a result of a  nonspecific T  cell deficit. 
There  is  evidence  that  EAE-resistant  BN  rats  fail  to  develop cellular  reactivity 
specific for the critical  disease  inducing  antigenic  determinant  (EF)  located  within 
amino  acid  residues  68-88  of the  BP  molecule  (13,  14). In  contrast,  it  has  been 
established that  Le rats develop cellular reactivity for BP and EF, and that BP and 
EF  specific  cellular  reactivity  is  detectable  after  primary and  secondary  BP-CFA 
challenge (7,  13-15).  It is possible that the resistance to EAE induction  displayed by 
Le-R rats is a  result of an impairment in their ability to develop EF-specific cellular 
reactivity  when  challenged  with  encephalitogenic  antigen.  In  order  to  test  this 
possibility, Le-R rats were challenged  with  BP-CFA  and subsequently  classified as 
susceptible or resistant.  At day 21  postchallenge, rats received a  second injection  of 
BP-CFA.  Cellular  reactivity  specific  for  BP  and  EF,  as  assessed  by  macrophage 
migration inhibition, was determined at day 21  after the second injection. 
Susceptible  and  resistant  Le-R  rats  developed  both  BP- and  EF-specific cellular 
reactivity after secondary challenge with BP-CFA (Fig. 4B and C). Similar data (not 
shown)  were obtained  at  day  21  after a  primary BP-CFA  injection.  Although  the 
remote  possibility of recognition  of a  nonencephalitogenic  determinant  on  the  19 
amino  acid  EF  molecule  cannot  be  rigorously  excluded  with  presently  available 
reagents, these data suggest that the clinical resistance to EAE induction displayed by 
Le-R rats is not caused by a failure to develop BP and EF specific cellular reactivity. 
Passive Transfer of EAE into Le-R Recipients.  Because Le-R rats developed EF-specific 
cellular reactivity, it was of interest  to determine if Le-R cells also had the capacity 
to  transfer  paralytic  EAE.  Conversely,  were  Le-R  rats  suitable  recipients  for  the 
passive transfer of EAE?  To address  these questions,  the recently described  passive 
transfer system of Pannitch  and McFarlin  (11)  and  Richert  et al.  (12)  was utilized. 68  RESISTANCE  TO  EXPERIMENTAL  ALLERGIC  ENCEPHALOMYELITIS 
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FIc.  4.  The development of cellular reactivity specific  for OA (panel A), intact BP (panel B), or 
EF (panel C) by EAE+susceptible  and EAE-resistant Le-R rats. Rats were challenged with BP-CFA 
at 7-8 wk of age (day 0), and classified  as EAE-susceptible (EAE-SENS) or EAE-resistant (EAE- 
REST). At day 21, rats in both groups were injected with either 100 IJg of OA in CFA or 50 ~g of 
BP in CFA.  Cellular reactivity was assessed  by a  direct macrophage migration inhibition assay 
performed at day 42. The data are expressed as percent inhibition of migration calculated by the 
following formula: 
(~ migration in the presence of antigen)] 
per cent inhibition =  1  ("-~ migratio------~  in the absence of antigen) .]  ×  100. 
When ~ migration in the presence of antigen exceeded ~ migration in the absence of antigen, data 
are expressed as percent enhancement. Four replicate capillary tubes were used for each antigen 
variable. As specificity  controls, naive rats were included in each assay. The values for these normal 
controls are expressed as a normal range (~n) reflecting the 95% confidence interval about the mean 
percent inhibition (or percent enhancement) measured in four experiments as described previously 
(7, 10). Each datum point (O) indicates the response of an individual rat. 
This  procedure,  which  involves  the  incubation  in  vitro of BP-sensitized  cells  in  the 
presence  of Con  A  or BP,  facilitates the induction  of EAE  of paralytic severity with 
a  relatively small number  of sensitized cells. Spleen cells were collected from paralyzed 
Le and  from asymptomatic  Le-R  rats at  day  12-14  after BP-CFA  challenge.  After a 
72-h in vitro culture period in the presence of Con A, the cells were infused into naive 
Le  and  Le-R  recipients  and  the  subsequent  development  of  clinical  EAE  was 
monitored. 
These  data  are  shown  in  Table  IV.  Spleen  cells obtained  from  BP-CFA-injected 
Le-R  rats  did  not  transfer  EAE  into  either  Le  or  Le-R  recipients.  In  contrast,  cells 
obtained  from  BP-CFA-injected  Le rats readily transferred EAE  into both  Le-R  and 
Le  recipients.  These  results  indicate  that  there  is  no  physiologic  barrier  to  EAE 
induction  in  Le-R  rats.  In  addition,  these  data  suggest  that  the  blockade  in  the WAXMAN,  PERRYMAN,  HINRICIHS, AND  COE 
TABLE  IV 
Passive Transfer of EAE into Le-R Recipients* 
No. of recipients  Cell  No. of viable cells 
donor  Recipient  transferred  with EAE/no. 
of rats tested 
Le-R  Le  3 X  107-10 X  107  0/12 
Le-R  Le-R  5 ×  107-10 X  107  0/6 
Le  Le  3 X  10 7  12/14 
Le  Le-R  3 X  I0  7  14/16 
* Donor spleen cells  were obtained  from Le or Le-R rats at day  12-14  post- 
BP-CFA  challenge.  The cells  were then  conditioned  in  vitro  for 3  d  and 
infused into normal recipients as described in Materials and Methods. The 
data  for the transfer of EAE into Le-R  recipients are compiled from three 
independent experiments in which the donor Le cells were incubated in vitro 
in the presence of Con A; similar data (not shown) were obtained in a fourth 
experiment in which the donor Le cells were cultured in vitro in the presence 
of BP. 
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induction  of EAE  in  Le-R rats  occurs  at  some point  during  the  differentiation  of 
antigen-reactive cells into EAE-inducing effector cells. 
Discussion 
The Le-R rat  is apparently a  mutant  Le rat. This genetic change is expressed as 
resistanceto clinical EAE induction.  Resistance was evident not only when Le-R rats 
were challenged with  the standard  encephalitogenic  dose for Le rats (50 #g of BP), 
but also when Le-R rats were challenged with up to 10 encephalitogenic doses of BP, 
or with an extremely potent mixture of spinal cord homogenate plus Bordetella pertussis 
extract  (not  shown).  In addition,  the  histologic  neural  tissue  lesions  that  typically 
accompany EAE are minimal or absent in EAE-resistant Le-R rats. 
Population  susceptibility  to  EAE  induction  appeared  to  increase  with  age  in 
randomly bred Le-R rats. Nevertheless, EAE rsistance was evident in both young and 
older  Le-R rats since the clinical  signs of neurologic dysfunction  were mitigated  in 
older animals. The phenomenon of increasing susceptibility with age was no longer 
apparent  by the Fa generation  of Le-R rats,  which  was resistant  at  all ages tested. 
Although  (Le  X  Le-R)F1  rats  were  resistant  to  EAE  induction  at  7-8  wk  of age, 
preliminary  observations  suggest  that  (Le  X  Le-R)F1  rats  are  susceptible  to  EAE 
induction at 36-40 wk of age. This suggests that the age-related susceptibility initially 
observed in randomly bred Le-R rats reflected the presence of rats with mixed Le X 
Le-R ancestry. The pattern of increasing susceptibility to disease with age may reflect 
an age-related loss in  suppressor cell function  as has been reported  in  autoimmune 
disease-prone mice  (16).  Alternatively, age-related  susceptibility  may be caused  by 
age-related  modulation  of the  specific effector cell  populations  involved  in  neural 
tissue destruction. 
Because some persistent viral infections have been reported to suppress immunologic 
function,  the  possibility  that  the  resistance  of Le-R  rats  was  of viral  etiology was 
considered. No evidence of depressed immunologic function was evident in Le-R rats 
by the criteria of their blastogenic response to mitogens in vitro (not shown), or their 
ability  to  develop  OA-specific  hypersensitivity  after  challenge  with  OA-CFA.  In 
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acquiring  resistance.  Finally,  the  F1  progeny resulting  from matings between  Le-R 
males  and  Le  females were  resistant  to  EAE  induction.  Because  the  pregnant  Le 
females were  separated  from the  Le-R  males before  the  birth  of litters,  these  rats 
manifested EAE resistance in the absence of direct contact with any Le-R rat. The Le 
mothers of these  progeny retained  their  EAE  susceptibility  in  spite of their  sexual 
contact  with  Le-R males  (not  shown).  Although  the  remote possibilities of the  Le 
females acquiring carrier status through contact with Le-R males, or a seminal fluid 
route of transmission, or that EAE induction in Le rats may be the result of activation 
of an encephalitogenic virus absent in Le-R rats cannot be excluded, it seems unlikely 
that the EAE resistance of Le-R rats involves persistent viral infection. 
EAE  resistance was not  a  universal phenomenon  in  the randomly bred Le-R.rat 
colony since a  small percentage of Le-R rats developed paralysis subsequent  to BP- 
CFA  challenge.  This  suggested  the  possibility  that  the  colony  might  contain  two 
distinct  populations:  one susceptible, the other resistant.  However, breeding experi- 
ments  indicated  that  F1  progeny  of  Le-R  rats,  selected  either  for  resistance  or 
susceptibility,  were  largely  EAE  resistant.  Further,  the  F2  progeny  derived  from 
susceptible parents and grandparents were as resistant to EAE induction as F2 rats of 
entirely resistant  lineage. Thus, susceptibility could not be selected for by breeding. 
Although  it  was  not  possible  to  produce  an  Fz  generation  of entirely  susceptible 
lineage because of the absence of brother-sister littermates in the very small group of 
F2 rats that were susceptible, the F3 generation of EAE-resistant lineage was uniformly 
resistant  suggesting that a  homogeneous population with phenotypic resistance had 
been selected. 
In order to determine if the EAE resistance of Le-R rats was a  genetic trait, Le-R 
rats  were  mated  with  Le  rats  and  the  EAE  susceptibility  of the  F~  progeny  was 
assessed. (Le ×  Le-R)F1 rats challenged at 7-8 wk of age displayed phenotypic EAE 
resistance  comparable  with  Le-R  rats.  Because  susceptibility  was  not  sex-linked, 
resistance appeared to be inherited as a dominant, autosomal trait. 
The  (Le  X  Le-R)F1  X  Le  backcross  progeny's susceptibility  to  EAE  induction 
segregated  in  a  ratio  of 25%  entirely  resistant  to  75%  susceptible.  The  susceptible 
group fell into two categories: approximately one-half (46%)  of the backcross popu- 
lation  developed  paralytic  EAE  whereas  the  remaining  29%  developed  EAE  with 
mitigated  neurologic  symptoms.  The  simplest  explanation  of  these  data  is  that 
resistance  is  mediated  by a  single  gene.  Variability  in  the  expression  of this  gene 
caused by some unknown extrinsic factor might account for the mitigated symptoms 
seen in some backcross animals. These data are also compatible with the hypothesis 
that  complete  EAE  resistance  is  dependent  upon  the  inheritance  of two  unlinked 
genes.  It is possible to speculate that  one of these genes may be a  strong resistance 
gene, the other a  relatively weak resistance gene.  Assuming that  the genes involved 
segregate in a Mendelian  fashion, one-fourth of the backcross progeny should inherit 
both  genes  thus  conferring  complete  EAE  resistance.  Another  one-fourth  of  the 
backcross rats would  be expected to  inherit  only the strong resistance  gene,  which 
theoretically  might  have the  capacity to mitigate but  not  completely abrogate the 
clinical signs of EAE in the absence of the weak resistance gene. The remaining one- 
half of the backcross population, which inherited either the weak resistance gene alone 
or  which  inherited  neither  of these  resistance  genes,  would  comprise  the  entirely 
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precise mapping of the resistance gene(s), and further delineation of the biological 
expression of the gene products. 
There is evidence that EAE susceptibility is dependent on the inheritance of an Ir 
gene  (Ir-EAE) closely linked  to the rat  MHC  (1-4). It seems likely that  Le-R rats 
possess  Ir-EAE because of the  following observations:  (a)  they develop EF-specific 
hypersensitivity, and  (b)  they share at  least  some common serologically detectable 
MHC  antigens  with  Le rats.  However, the  possibility of a  genetic  recombination 
occurring between the loci controlling the production ofserologicaUy detectable MHC 
antigens and the putative Ir-EAE locus is not precluded. 
Based  on  observations  reported  here  and  elsewhere,  it  is  possible  to  design  a 
theoretical model of the events leading to the induction of EAE (Fig. 5). The injection 
of BP-CFA initiates the development of antigen-reactive T  lymphocytes with specific- 
ity for the encephalitogenic determinant(s)  on the BP molecule. The failure of BN 
rats to develop EAE is apparently a result of a deficit at this step because BN rats do 
not  develop detectable EF-specific hypersensitivity (13,  14).  In contrast, Le-R rats 
evidently develop specific antigen-reactive cells, as assessed by macrophage migration 
inhibition  in  the  presence of BP  or  EF.  However, these  data  do  not  exclude the 
possibility that  Le-R rats may develop smaller numbers of specific antigen-reactive 
cells  than  Le rats.  Subsequent  steps  in  the  induction  of EAE  require  the  in  vivo 
differentiation  (step  2)  of antigen-reactive cells  into  EAE  effector precursor cells, 
which  can  be  educated  (step  3)  by  incubation  in  vitro  in  the  presence of either 
polyclonal (Con A) or specific (BP or EF) culture stimulants to develop into educated 
EAE effector cells. There is evidence  2 that  both steps 2  and  3 are required for the 
adoptive transfer of EAE by rat spleen cells since of the following criteria: (a) large 
numbers of guinea pig BP-sensitized Le cells fail  to transfer EAE unless  they are 
incubated in vitro in the presence of either Con A or encephalitogenic antigen, and 
(b) cells from Le rats, which had not been sensitized with encephalitogenic antigen, 
fail to transfer EAE  in  spite of in vitro conditioning in the presence of Con A  or 
encephalitogenic antigen. However, it is possible that the in vitro culture period may 
involve the  clonal  expansion  of EAE  effector cells or reduction  in  the  activity of 
suppressor cells, rather than  differentiation of effector cells from effector precursor 
cells.  The educated EAE effector cells have the capacity to induce clinical EAE (step 
4) after adoptive transfer into naive recipients. Le-g rats are not blocked at step 4 in 
this process since they develop paralytic EAE after the adoptive transfer of Con A- or 
BP-stimulated effector cells obtained from BP-CFA-sensitized Le rats. The adoptive 
BP-CFA  step 1 
X  / 
Anttgen-roactfve  T  l~phocytes 
j~Ef  X  Step  2 
ctor  precursor  cells 
~li~x  Step  3  (in  vitro) 
Cltntcal  EAE  ~  Step 4  Educated  effect0r cells 
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transfer of paralytic EAE into Le-R rats by sensitized Le leukocytes is striking in view 
of previously established genetic restrictions which preclude the transfer of EAE from 
Le into allogeneic or even MHC-compatible rat strains, z In the reciprocal transfer, Le 
rats did not develop EAE after adoptive transfer of Le-R cells. This may reflect a one- 
way allogeneic recognition of Le-R cells by Le rats;  however, preliminary evidence 
suggests that  Le and  Le-R leukocytes are  mutually  nonreactive  in  one-way mixed 
leukocyte reactions, and that Le but not Le-R cells have the capacity to transfer EAE 
into  (Le ×  Le-R)F1 recipients.  Thus, the resistance to EAE  induction  displayed by 
Le-R rats may be a result of a deficit in the differentiation of antigen-reactive cells to 
effector precursor  cells  in  vivo  (step  2),  and/or  the  further  development  of active 
effector cells during the in vitro culture period (step 3). 
The apparent  feasibility of nonrestricted cellular exchange between Le and Le-R 
rats presents  a  unique  opportunity  to investigate cellular resistance mechanisms in 
EAE.  Disease  resistance  in  the  Le-R  rat  may  reflect  a  deficiency  in  a  leukocyte 
population  required  for EAE induction.  Because  7- to 8-wk-old (Le ×  Le-R)Fa rats 
were  resistant  to  EAE  induction,  gene  complementation  evidently  does  not  occur 
when Le and Le-R genes are juxtaposed in a trans configuration. Alternatively, EAE 
resistance  in  the  Le-R rat  may be caused by an excessive production  of suppressor 
cells  and/or  regulatory  macromolecules.  There  is  evidence  suggesting  that  both 
antigen-specific and  nonspecific humoral  factors may mediate EAE resistance  (17- 
19). However, preliminary evidence suggests that the infusion of Le-R serum into Le 
rats does not alter their susceptibility to EAE induction.  Disease resistance in the Le- 
R  rat  may reflect  an  imbalance in  a  nonspecific suppressor cell  population  as  has 
been reported  in  association with  a  canine demyelinating disease  (20,  21),  or from 
hyperreactivity  in  populations  of  BP-specific  suppressor  cells,  which  have  been 
identified  in  both  protected  and  EAE-recovered Le rats  (22-26).  Further  efforts to 
delineate more precisely the nature of EAE resistance in  Le-R rats are currently in 
progress. 
Summary 
Clinical resistance to the induction of experimental allergic encephalomyelitis was 
observed in a closed colony of Lewis (designated Le-R) rats. Disease susceptibility in 
randomly bred animals appeared to increase with increasing age. In the small group 
of young  Le-R rats,  which  were susceptible,  disease onset  was  delayed,  severity of 
symptoms was reduced, and duration  of clinical signs was abbreviated compared to 
conventional Lewis rats. The severity of histologic neural tissue lesions correlated with 
clinical  observations.  Breeding  experiments  indicated  that  most  Le-R  rats  were 
resistant  to disease induction  regardless of whether their ancestors had been selected 
for susceptibility or resistance. The F3 generation of resistant  lineage was uniformly 
resistant  at  all  ages  tested.  Virtually  all  (Lewis  ×  Le-R)F1  rats  of either  sex were 
resistant when challenged at 7-8 wk of age indicating that resistance was a dominant 
autosomal trait. Approximately half of (F1 X Lewis) backcross rats developed paralytic 
EAE whereas one-fourth were entirely resistant, suggesting that disease resistance may 
be mediated  by one or two genes.  Le-R rats shared  at  least  some of the  Lewis rat 
major histocompatibility antigens. Resistance apparently did not reflect a nonspecific 
impairment of cellular immune responsiveness. Le-R rats, which had been challenged 
with  myelin basic protein, developed antigen-reactive cells specific for basic protein WAXMAN, PERRYMAN,  HINRICHS, AND COE  73 
or its encephalitogenic  fragment.  Spleen cells obtained  from basic protein-sensitized 
Le-R rats did not adoptively transfer disease into Lewis rats.  In contrast, spleen cells 
obtained from basic protein-sensitized  Lewis rats readily transferred disease into both 
Lewis and Le-R recipients.  These data suggest that disease resistance may be a result 
of an immunologic deficit  (or suppressor cell activity) expressed during the differen- 
tiation of antigen-reactive cells into disease-inducing effector cells. 
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